Invesco Reports 5.4% Integra LifeSciences Stake — Adviser Clients Own The Shares

The passive position covered 4,164,366 shares, with no individual client holding more than 5% economic ownership.

Share
Invesco Reports 5.4% Integra LifeSciences Stake — Adviser Clients Own The Shares

Invesco reported a 5.4% stake in Integra LifeSciences, which makes medical devices, in a passive ownership disclosure filed Tuesday. The 4,164,366 shares were held by investment-adviser clients, with ownership attributed to Invesco as the advisers' parent holding company.

Clients Keep The Economic Rights

The position was measured as of September 30. Invesco's reported beneficial ownership — the basis used to attribute the stake to the parent — differs from an individual client's economic interest: no client held more than 5% economic ownership.

The clients have the rights to dividends and money from share sales. The disclosure named Invesco Advisers and Invesco Capital Management as the investment advisers and reported sole voting authority over 4,164,293 shares, with no shared voting authority.

Invesco certified that the shares were held through ordinary business activity, rather than for an effort to change or influence Integra's control.

Profit, A Neutral Rating And A Gain

Integra reported third-quarter revenue of $411.2 million and earnings of $14.9 million, producing a 3.61% profit margin. UBS maintained its Neutral rating on October 27 and lowered its price target.

IART shares soared 7.08% to $14.37 at the November 9 close. Integra's market capitalization was $1.1 billion as of Tuesday at 4:09 p.m. ET; the earlier share-price gain provides context for the ownership report, rather than a reaction to it.

Integra supplies products for neurosurgery, wound care and tissue repair, including products that repair the protective membrane around the brain, fill bone voids and repair nerves and tendons. Some use bovine or porcine tissue; products containing bovine-derived material accounted for 26% of revenue in 2025.

The reported 5.4% stake represents shares held across adviser clients, whose dividend and sale-proceeds rights remain their own.

Sources

More on Integra LifeSciences

All Integra LifeSciences (IART) coverage →